Short Interest in BR Biopharma, Inc. (NASDAQ:BRBI) Drops By 65.4%

BR Biopharma, Inc. (NASDAQ:BRBI) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,225 shares, a decline of 65.4% from the August 15th total of 3,543 shares. Based on an average trading volume of 1,065 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th biggest position.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BR Biopharma in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

BR Biopharma Stock Down 1.2%

NASDAQ:BRBI opened at $11.22 on Friday. The company has a market cap of $132.52 million and a P/E ratio of 140.26. The firm’s 50 day moving average is $10.82 and its two-hundred day moving average is $12.76. BR Biopharma has a fifty-two week low of $9.09 and a fifty-two week high of $67.01.

BR Biopharma (NASDAQ:BRBI) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 EPS for the quarter. The firm had revenue of $25.13 million for the quarter.

BR Biopharma Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Monday, August 17th were paid a dividend of $0.1415 per share. The ex-dividend date was Monday, August 17th. This represents a $0.57 annualized dividend and a yield of 5.0%. BR Biopharma’s dividend payout ratio is currently 525.00%.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.